January 11, 2023
Life Sciences
  • The Food and Drug Administration (FDA) said its advisory panel will meet on February 15 to review Emergent Biosolutions Inc’s over-the-counter nasal spray to treat suspected opioid overdoses. Emergent is asking the FDA to approve for the prescription-free sale of Narcan, its nasal spray form of the drug naloxone. Narcan is already cleared for the treatment of opioid overdose in the country. (Article here)
Return to Tea Leaves